교수진 소개
- Name
- Heejung CHAE
- Faculty Appointment:
(title, department)
- Assistant Professor, Department of Cancer Biomedical Science
- Area of Expertise
- Translational cancer research, Healthcare data research
- Contact no
- +82-31-920-1716
- E-mail
- hchae21@ncc.re.kr
- Work Experience
- Mar 2013 – Feb 2014 Internship
Asan Medical Center,
University of Ulsan College of Medicine , Seoul, Korea
Mar 2014 – Feb 2018 Residency
Department of Internal Medicine
Asan Medical Center,
University of Ulsan College of Medicine, Seoul, Korea
Mar 2018 – Oct 2019 Clinical Fellowship
Department of Medical Oncology
Asan Medical Center,
University of Ulsan College of Medicine, Seoul, Korea
Nov 2019 – present Medical Oncology
Breast Cancer Center
National Cancer Center, Goyang, Korea
Oct 2020 – present Senior Scientist
Cancer Data Center
National Cancer Center, Goyang, Korea
- Educational Background
- Mar 2007 – Feb 2013, M.D. University of Ulasn
Mar 2016 – Feb 2018, M.S. University of Ulasn
Mar 2018 – Feb 2020, Ph.D. University of Ulasn
- Research Interests
- Heejung Chae, MD, PhD, is a medical oncologist focusing on the care of breast cancer patients, and has particular interest in the translational research and healthcare data research.
- International Collaboration
- Academic Committee, Global Breast Cancer Conference
Member, American Society of Clinical Oncology
Member, European Society of Medical Oncology
Member, American Association of Cancer Research
- Achievements
-
2023 SCI-E Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer: CANCERS. 15(18):4451~ (5.2)
2023 SCI-E Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients: CANCER RESEARCH AND TREATMENT. 55(4):1077~1086 (4.6)
2023 SCI-E Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: CANCERS. 15(10):2810~ (5.2)
2023 SCI-E Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study: BREAST CANCER-TARGETS AND THERAPY. 15:251~261 (2.6)
2022 SCI-E Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor?Positive and HER-2?Negative Breast Cancer with Neoadjuvant Chemotherapy: CANCER RESEARCH AND TREATMENT. Online:Published (5.036)
2022 SCI-E Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer The Neo-PATH Phase 2 Nonrandomized Clinical Trial: JAMA ONCOLOGY. 8(9):1271~1277 (33.012)
2022 SCI-E Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09): CANCER RESEARCH AND TREATMENT. Online:Published (5.036)
2022 SCI-E Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single-Center Experience over 25 Years and Evaluation of PD-L1 Expression: CANCER RESEARCH AND TREATMENT. 54(2):579~589 (4.679)
2021 SCI-E Clinical Effectiveness of Hypofractionated Proton Beam Therapy for Liver Metastasis from Breast Cancer: FRONTIERS IN ONCOLOGY. 11:783327~ (6.244)
2021 SCI-E Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent?based analysis: BLOOD ADVANCES. 5(8):2142~2152 (6.799)
2021 SCI-E The limited role of comprehensive staging work-up in ocular adnexal extranodal marginal zone lymphoma of mucosaassociated lymphoid tissue type (MALToma) with excellent prognosis: BRITISH JOURNAL OF HAEMATOLOGY. 193(4):848~851 (6.998)
2021 SCI-E The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study: FRONTIERS IN ONCOLOGY. 11:653243~ (6.244)
2021 SCI-E Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2?Targeted Agent in the Real-World Setting: CANCER RESEARCH AND TREATMENT. 53(2):436~444 (3.761)
2020 SCI-E Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. Online:Published (6.852)
2020 SCI-E Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP.: LEUKEMIA & LYMPHOMA. Online:Published (2.969)
2019 SCI-E Impact of L-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor: INVESTIGATIONAL NEW DRUGS. 38:493~499 (2.663)
2019 SCI-E Therapeutic Relevance of Targeted Sequencing in Management of Patients with Advanced Biliary Tract Cancer: DNA Damage Repair Gene Mutations as a Predictive Biomarker: EUROPEAN JOURNAL OF CANCER. 120:31~39 (6.68)
2019 기타 Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma: Korean Journal of Medicine. 92(2):152~158 (0)
2019 SCI-E Long?term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14?year, single?center experience: CANCER MEDICINE. 8(3):1034~1043 (3.357)
2018 SCI-E Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin: INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS. :~ (1.746)
2018 SCI-E FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment: JOURNAL OF BREAST CANCER. 21(1):45~50 (2.241)
2016 SCI-E Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor: CANCER CHEMOTHERAPY AND PHARMACOLOGY. :~ (2.967)
2012 SCI-E EUS-guided radiofrequency ablation of the porcine pancreas: GASTROINTESTINAL ENDOSCOPY. :~ (6.89)
